BioNexus (BGLC) CFO Chong Set Fui Receives Stock Award

What Happened
Chong Set Fui, Chief Financial Officer of BioNexus Gene Lab Corp (BGLC), was granted a fully vested other stock-based award of 96,774 shares on August 13, 2026. The award was granted for completed services with no cash paid; for plan purposes it was valued at $1.55 per share (Nasdaq close on Aug 12, 2026), roughly $150,000 total. This was an award/grant (code A), not an open-market purchase or sale.

Key Details

• Transaction date: August 13, 2026 (Form 4 filed August 14, 2026 — timely).
• Award: 96,774 shares; plan valuation: $1.55 per share (Nasdaq close 8/12/2026).
• Consideration: No cash paid; granted for completed services; fully vested on grant.
• Shares owned after transaction: Not disclosed in the filing.
• Footnote: Award granted under the BioNexus Gene Lab Corp. 2025 Equity Incentive Plan (see F1).
• Filing timeliness: Report filed the next day (no late-report indication).

Context
This is a compensation award (fully vested on grant) rather than a purchase or sale, so it reflects pay rather than the CFO buying or selling stock for investment reasons. Such grants increase the insider’s holdings and can dilute existing shareholders over time; the reported value is for plan/accounting purposes based on the closing market price and does not represent cash received.